Seminars in Oncology
Volume 31, Issue 4 , Pages 498-512 , August 2004

Premalignant lesions of the esophagogastric mucosa

  • R. Lambert

      Affiliations

    • International Agency for Research on Cancer, Lyon, France
    • Corresponding Author InformationAddress reprint requests to Rene Lambert, MD, International Agency for Research on Cancer, 150 cours Albert Thomas, Lyon 69008 France
    • ,
  • P. Hainaut

      Affiliations

    • International Agency for Research on Cancer, Lyon, France
    • ,
  • D.M. Parkin

      Affiliations

    • International Agency for Research on Cancer, Lyon, France

References 

  1. Guindi M, Riddell RH. The pathology of epithelial premalignancy of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2001;15:191–210
  2. Jass JR, Talbot IC. Molecular and cellular biology of premalignancy in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2001;15:175–189
  3. Ferlay J, Bray F, Pisani P, et al.  Globocan 2000. Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, France: IARC Press; 2001;
  4. Makuuchi H. Endoscopic mucosal resection for mucosal cancer in the esophagus. Gastrointest Endosc Clin North Am. 2001;11:445–458
  5. Ono H, Kondo H, Gotoda T, et al.  Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48:225–229
  6. Lambert R. Treatment of esophagogastric tumors. Endoscopy. 2003;35:118–126
  7. Shim CS. Endoscopic mucosal resection (An overview of the value of different techniques). Endoscopy. 2001;33:271–275
  8. Spechler SJ. Clinical practice. Barrett’s esophagus. N Engl J Med. 2002;346:836–842
  9. Glickman JN, Chen YY, Wang HH, et al.  Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett’s esophagus. Am J Surg Pathol. 2001;25:569–578
  10. Shields HM, Rosenberg SJ, Zwas FR, et al.  Prospective evaluation of multilayered epithelium in Barrett’s esophagus. Am J Gastroenterol. 2001;96:3268–3273
  11. Zhang Z, Yuan Y, Gao H, et al.  Apoptosis, proliferation and p53 gene expression of H. pylori associated gastric epithelial lesions. World J Gastroenterol. 2001;7:779–782
  12. Petersson F, Borch K, Franzen LE. Gastric epithelial proliferation and p53 and p21 expression in a general population sample (relations to age, sex, and mucosal changes associated with H. pylori infection). Dig Dis Sci. 2002;47:1558–1566
  13. Wang J, Chi DS, Kalin GB, et al.  Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci. 2002;47:107–113
  14. Wambura C, Aoyama N, Shirasaka D, et al.  Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics (Implication for gastric carcinogenesis). Helicobacter. 2002;7:129–138
  15. Yang A, Schweitzer R, Sun D, et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714–718
  16. DeLaurenzi V, Rossi A, Terrinoni A, et al.  p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun. 2000;273:342–346
  17. Hainaut P, Hollstein M. p53 and human cancer (The first ten thousand mutations). Adv Cancer Res. 2000;77:81–137
  18. Si HX, Tsao SW, Poon CS, et al.  Viral load of HPV in esophageal squamous cell carcinoma. Int J Cancer. 2003;103:496–500
  19. Yokoyama A, Omori T. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. Jpn J Clin Oncol. 2003;33:111–121
  20. Tanière P, Martel-Planche G, Maurici D, et al.  Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol. 2001;158:33–40
  21. Zhang ZF, Kurtz RC, Klimstra DS, et al.  Helicobacter pylori infection and the risk of stomach cancer and chronic atrophic gastritis. Cancer Detect Prev. 1999;23:357–367
  22. Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest. 2001;107:767–773
  23. Parkin DM, Ferlay J, Hamdi Cherif M, et al.  Cancer in Africa. Epidemiology and Prevention. Lyon, France: IARC Press; 2003;
  24. Campbell DI, Warren BF, Thomas JE, et al.  The African enigma (Low prevalence of gastric atrophy, high prevalence of chronic inflammation in West African Adults and children). Helicobacter. 2001;6:263–267
  25. Danesh J. Helicobacter pylori infection and gastric cancer (Systematic review of the epidemiological studies). Aliment Pharmacol Ther. 1999;13:851–856
  26. Helicobacter and Cancer Collaborative Group . Gastric cancer and Helicobacter pylori (A combined analysis of 12 case-control studies nested within prospective cohorts). Gut. 2001;49:347–353
  27. Wu AH, Crabtree JE, Bernstein L, et al.  Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer. 2003;103:815–821
  28. Rugge M, Correa P, Dixon MF, et al.  Gastric dysplasia; the Padova international classification. Am J Surg Pathol. 2000;254:167–176
  29. Schlemper RJ, Riddell RH, Kato Y, et al.  The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–255
  30. Dixon MF. Gastrointestinal epithelial neoplasia (Vienna revisited). Gut. 2002;51:130–131
  31. Gao H, Wang LD, Zhou Q, et al.  p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res. 1994;54:4342–4346
  32. Couvelard A, Cauvin JM, Goldfain D, et al.  Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut. 2001;49:761–766
  33. Odze R. Cytokeratin 7/20 immunostaining (Barrett’s oesophagus or gastric intestinal metaplasia?). Lancet. 2002;359:1711–1713
  34. Shen B, Ormsby AH, Shen C, et al.  Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma (Implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction). Cancer. 2002;94:820–831
  35. Tanière P, Borghi-Scoazec G, Saurin JC, et al.  Cytokeratin expression in adenocarcinomas of the esophagogastric junction (A comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach). Am J Surg Pathol. 2002;26:1213–1221
  36. Wu TT, Watanabe T, Heitmiller R, et al.  Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol. 1998;153:287–294
  37. Montesano R, Hainaut P. Molecular precursor lesions in oesophageal cancer. Cancer Surv. 1998;32:53–68
  38. El-Rifai W, Frierson HF, Moskaluk CA, et al.  Genetic differences between adenocarcinomas arising in Barrett’s esophagus and gastric mucosa. Gastroenterology. 2001;121:592–598
  39. Correa P. Human gastric carcinogenesis (A multistep and multifactorial process—First American Cancer Society Award lecture on cancer epidemiology and prevention). Cancer Res. 1992;52:6735–6740
  40. Lee JH, Abraham SC, Kim HS, et al.  Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol. 2002;161:611–618
  41. Torbenson M, Lee JH, Cruz-Correa M, et al.  Sporadic fundic gland polyposis (A clinical, histological, and molecular analysis). Mod Pathol. 2002;15:718–723
  42. Abraham SC, Singh VK, Yardley JH, et al.  Hyperplastic polyps of the stomach (Associations with histologic patterns of gastritis and gastric atrophy). Am J Surg Pathol. 2001;25:500–507
  43. Muehldorfer SM, Stolte M, Martus P, et al.  Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps (A prospective multicentre study). Gut. 2002;50:465–470
  44. Ohkusa T, Takashimizu I, Fujiki K, et al.  Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann Intern Med. 1998;129:712–715
  45. Abraham SC, Park SJ, Mugartegui L, et al.  Sporadic fundic gland polyps with epithelial dysplasia (Evidence for preferential targeting for mutations in the adenomatous polyposis coli gene). Am J Pathol. 2002;161:1735–1742
  46. Inoue H, Rey JF, Lightdale C. Lugol chromoendoscopy for esophageal squamous cell cancer. Endoscopy. 2001;33:75–79
  47. Shimizu Y, Tukagoshi H, Fujita M, et al.  Endoscopic screening for early esophageal cancer by iodine staining in patients with other current or prior primary cancers. Gastrointest Endosc. 2001;53:1–5
  48. Endo T, Awakawa T, Takahashi H, et al.  Classification of Barrett’s epithelium by magnifying endoscopy. Gastrointest Endosc. 2002;55:641–647
  49. Guelrud M, Herrera I, Essenfeld H, et al.  Enhanced magnification endoscopy (A new technique to identify specialized intestinal metaplasia in Barrett’s esophagus). Gastrointest Endosc. 2001;53:559–565
  50. Kumagai Y, Inoue H, Nagai K, et al.  Magnifying endoscopy, stereoscopic microscopy, and the microvascular architecture of superficial esophageal carcinoma. Endoscopy. 2002;34:369–375
  51. Sharma P, Weston AP, Topalovski M, et al.  Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s oesophagus. Gut. 2003;52:24–27
  52. Tajiri H, Doi T, Endo H, et al.  Routine endoscopy using a magnifying endoscope for gastric cancer diagnosis. Endoscopy. 2002;34:772–777
  53. Yao K, Oishi T. Microgastroscopic findings of mucosal microvascular architecture as vizualized by magnifying endoscopy. Dig Endosc. 2001;13(suppl):S27–S33
  54. Lambert R, Rey JF, Sankaranarayanan R. Magnification and chromoscopy with the acetic acid test. Endoscopy. 2003;35:437–445
  55. Rollins AM, Sivak MV. Potential new endoscopic techniques for the earlier diagnosis of premalignancy. Best Pract Res Clin Gastroenterol. 2001;15:227–247
  56. Japanese Gastric Cancer Association . Japanese Classification of Gastric Carcinoma. 2nd English edition Gastric Cancer. 1998;1:10–24
  57. Japanese Society for Esophageal Diseases . In: Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. (ed 9). Tokyo, Japan: Kanehara; 1999;
  58. Dawsey SM, Lewin KJ, Wang GQ, et al.  Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow up study from Linxian, China. Cancer. 1994;74:1686–1692
  59. Dawsey SM, Lewin KJ, Liu FS, et al.  Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients. Cancer. 1994;73:2027–2237
  60. Qiu SL, Yang GR. Precursor lesions of esophageal cancer in high risk populations in Henan province, China. Cancer. 1988;62:551–557
  61. Katakura T, Masuda T, Ikeda T, et al.  Immunohistochemical studies in depressed type adenomas of the stomach. Comparison with protruded type adenomas and depressed type well differentiated mucosal gastric cancer. (in Japanese) Nippon Shokakibyo Gakkai Zasshi. 1998;95:992–1000
  62. Xuan ZX, Ambe K, Enjoji M. Depressed adenoma of the stomach, revisited. Histologic, histochemical and immunochemical profiles. Cancer. 1991;67:2382–2389
  63. Schmitz GM, Stolte M. Gastric polyps and precancerous lesions. Gastrointest Endosc Clin North Am. 1997;7:29–46
  64. Stolte M. Clinical consequences of the endoscopic diagnosis of gastric polyps. Endoscopy. 1995;27:32–37
  65. Stolte M, Sticht T, Eidt S, et al.  Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy. 1994;26:659–665
  66. Stolte M. Hyperplastic polyps of the stomach (Associations with histologic patterns of gastritis and gastric atrophy). Am J Surg Pathol. 2001;25:1342–1344
  67. Park DI, Rhee Pl, Kim JE, et al.  Factors suggesting malignant transformation of gastric adenoma (Univariate and multivariate analysis). Endoscopy. 2001;33:501–506
  68. Kodama M, Kakegawa T. Treatment of superficial cancer of the esophagus (A summary of responses to a questionnaire on superficial cancer of the esophagus in Japan). Surgery. 1998;123:432–439
  69. National Report of the Group Medical Examination for Digestive Cancer in 1999. (in Japanese) J Gastroenterol Mass Sur. 2002;40:57–76
  70. Hosokawa O, Tsuda S, Kidani E, et al.  Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy. 1998;30:669–741
  71. Hosokawa O, Watanabe K, Hatorri M, et al.  Detection of gastric cancer by repeat endoscopy within a short time after negative examination. Endoscopy. 2001;33:301–305
  72. Lambert R, Guilloux A, Oshima A, et al.  Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer. 2002;97:811–818
  73. Canto MI, Setrakian S, Willis JE, et al.  Methylene blue staining of dysplastic and non dysplastic Barrett’s esophagus (An in vivo and ex vivo study). Endoscopy. 2001;33:391–400
  74. Levine DS, Blount PL, Rudolph RE, et al.  Safety of a systematic endoscopic biopsy protocol in patients with Barrett’s esophagus. Am J Gastroenterol. 2000;95:1152–1157
  75. Tsukuma H, Oshima A, Narahara H, et al.  Natural history of early gastric cancer (A non concurrent long term follow up study). Gut. 2000;4:618–621
  76. Wang GQ, Dawsey SM, Li JY, et al.  Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach (Results from the General Population Trial in Linxian, China). Cancer Epidemiol Biomarkers Prev. 1994;3:161–166
  77. Ye W, Chow WH, Lagergren J, et al.  Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121:1286–1293
  78. Fennerty MB, Triadafilopoulos G. Barrett’s-related esophageal adenocarcinoma (Is chemoprevention a potential option?). Am J Gastroenterol. 2001;96:2302–2305
  79. Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology. 2003;124: 1758–1756
  80. Malila N, Taylor PR, Virtanen MJ, et al.  Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland). Cancer Causes Control. 2002;13:617–623
  81. Watanabe H, Komukai S, Ajioka Y, et al.  Histopathology of m3 and sm1 invasive squamous cell carcinoma of the esophagus with special reference to endoscopic resection. (in Japanese) Stomach Intestine. 1998;33:985–992
  82. May A, Gossner L, Pech O, et al.  Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment barrett’s esophagus (SSBE) (Curative treatment using local endoscopic treatment techniques). Endoscopy. 2002;34:604–610
  83. Pech O, Gossner A, May A, et al.  Management of Barrett’s esophagus, dysplasia and early adenocarcinoma. Best Pract Res Clin Gastroenterol. 2001;15:267–284
  84. Pech O, Nagy CD, Gossner L, et al.  Photodynamic therapy of human Barrett cancer using 5-aminolaevulinic acid induced protoporphyrin IX (An in vivo dosimetric study in athymic nude mice). Eur J Gastroenterol Hepatol. 2002;14:657–662
  85. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2002;16:41–50
  86. Whithing JL, Sigurdsson A, Rowlands DC, et al.  The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 2002;50:378–381
  87. Kokkola A, Sipponen P, Rautelin H. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther. 2002;16:515–520

PII: S0093-7754(04)00238-6

doi: 10.1053/j.seminoncol.2004.04.017

Seminars in Oncology
Volume 31, Issue 4 , Pages 498-512 , August 2004

Article Tools

* Image Usage & Resolution